These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 20807330)

  • 21. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
    Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
    J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome.
    Saad F; Gooren L; Haider A; Yassin A
    Andrologia; 2008 Feb; 40(1):44-8. PubMed ID: 18211301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Symptomatic response to testosterone treatment in dieting obese men with low testosterone levels in a randomized, placebo-controlled clinical trial.
    Ng Tang Fui M; Hoermann R; Prendergast LA; Zajac JD; Grossmann M
    Int J Obes (Lond); 2017 Mar; 41(3):420-426. PubMed ID: 28028318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
    Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Testosterone Therapy Improves Urinary and Sexual Function, and Quality of Life in Men with Hypogonadism: Results from a Propensity Matched Subgroup of a Controlled Registry Study.
    Haider KS; Haider A; Doros G; Traish A
    J Urol; 2018 Jan; 199(1):257-265. PubMed ID: 28728990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.
    Corona G; Rastrelli G; Morgentaler A; Sforza A; Mannucci E; Maggi M
    Eur Urol; 2017 Dec; 72(6):1000-1011. PubMed ID: 28434676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale.
    Ho CC; Tong SF; Low WY; Ng CJ; Khoo EM; Lee VK; Zainuddin ZM; Tan HM
    BJU Int; 2012 Jul; 110(2):260-5. PubMed ID: 22093057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Profile of serum testosterone levels after application of testosterone ointment (glowmin) and its clinical efficacy in late-onset hypogonadism patients.
    Amano T; Imao T; Takemae K; Iwamoto T; Yamakawa K; Baba K; Nakanome M; Sugimori H; Tanaka T; Yoshida K; Katabami T; Tanaka M
    J Sex Med; 2008 Jul; 5(7):1727-36. PubMed ID: 18093097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome.
    Saad F; Gooren L; Haider A; Yassin A
    Arch Androl; 2007; 53(6):353-7. PubMed ID: 18357966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Tadalafil improves total testosterone, IIEF score and SEP in old and middle-aged males with late-onset hypogonadism].
    Wang XK; Luo L; Wang S; Li J; Li WX
    Zhonghua Nan Ke Xue; 2012 May; 18(5):475-7. PubMed ID: 22741450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement.
    El-Sakka AI; Hassoba HM; Elbakry AM; Hassan HA
    J Sex Med; 2005 Mar; 2(2):235-40. PubMed ID: 16422891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study.
    Legros JJ; Meuleman EJ; Elbers JM; Geurts TB; Kaspers MJ; Bouloux PM;
    Eur J Endocrinol; 2009 May; 160(5):821-31. PubMed ID: 19211706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.
    Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N;
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2839-53. PubMed ID: 10946892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of continuous long-term testosterone therapy (TTh) on anthropometric, endocrine and metabolic parameters for up to 10 years in 115 hypogonadal elderly men: real-life experience from an observational registry study.
    Yassin AA; Nettleship J; Almehmadi Y; Salman M; Saad F
    Andrologia; 2016 Sep; 48(7):793-9. PubMed ID: 26762680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late-onset hypogonadism in the aging male (LOH): definition, diagnostic and clinical aspects.
    Schubert M; Jockenhövel F
    J Endocrinol Invest; 2005; 28(3 Suppl):23-7. PubMed ID: 16042356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate.
    Minnemann T; Schubert M; Hübler D; Gouni-Berthold I; Freude S; Schumann C; Oettel M; Ernst M; Mellinger U; Sommer F; Krone W; Jockenhövel F
    Aging Male; 2007 Sep; 10(3):155-8. PubMed ID: 17701659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
    Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Berman N; Hull L; Swerdloff RS
    J Clin Endocrinol Metab; 2004 May; 89(5):2085-98. PubMed ID: 15126525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome.
    Aversa A; Bruzziches R; Francomano D; Spera G; Lenzi A
    J Endocrinol Invest; 2010 Dec; 33(11):776-83. PubMed ID: 20220293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial.
    Gianatti EJ; Dupuis P; Hoermann R; Zajac JD; Grossmann M
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3821-8. PubMed ID: 24978674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
    Honig S; Gittelman M; Kaminetsky J; Wang C; Amory JK; Rohowsky N; Dudley RE; Woun Seo B; Newmark J; Swerdloff R
    J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.